Application of biochemical tumor markers in the diagnostics and monitoring of melanoma
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 6
Abstract
Laboratory diagnostics plays a crucial role in oncological diagnosis of cancers especially in the first stage of tumor progression. The early detection of tumor markers (TM) in peripheral blood or tumor tissue of patients with cancer has particular significance for staging, prognosis and monitoring of the disease. TM can be defined as an antigenic protein, glycoprotein or enzyme which is produced by tumor or normal cells and is released to the blood during the neoplastic process. Melanoma shows a high metabolic activity, which is characterized by elevated synthesis of different kinds of proteins, cytokines and enzymes. Most of them are identified and utilized in clinical diagnosis procedures. Among antigens associated with melanoma progression, determination of the S100, MIA and TA90 is most valuable, both for the early detection of cancer and for the monitoring of the treatment strategy. An increase of melanine synthesis during melanoma progression generates augmentation of 5-SCD and indol derivates production, which is detectable in the blood and urine. Numerous investigations in clinical diagnosis have been focused on the evaluation of the cytokines and adhesion molecules expression in order to identify the interaction between tumor cells and host immune response. A recent investigation revealed the role of angiogenic factors in melanoma progression. Routine laboratory determination of LDH or CRP level is important for the monitoring of the treatment results. Currently, numerous investigations have been performed to find out the most specific marker for the early stage of melanoma or minimal residual disease detection and supervision. However, the unsatisfactory diagnostic sensitivity and specificity of the newly discovered candidate is the major obstacle for the regular application in the clinical practice. Usefulness of currently available diagnostic markers is limited to monitoring of the remission of the disease for the period of treatment process and detection of metastases or relapse of cancer.
Authors and Affiliations
Ewa Leporowska, Aldona Kaczmarek, Katarzyna Lamperska, Andrzej Mackiewicz
Keywords
Related Articles
- EP ID EP139118
- DOI -
- Views 41
- Downloads 0
Choroba Leśniowskiego-Crohna a rak jelita grubego
Nieswoiste, ziarniniakowe zapalenie jelit, nazwane chorobą Leśniowskiego-Crohna jest jednym ze schorzeń, predysponujących do powstania raka jelita grubego. Częstość zachorowań rośnie wraz z postępem cywilizacyjnym społ...
The role of oestrogenes in carcinogenesis.
Both oestrogens and their metabolites are believed to be etiological factors in breast, uterine and ovarian carcinomas. Those hormones stimulate the proliferation of cells, which proceeded by DNA replication, offers the...
Clinical significance of apoptotic index in non-smell cell lung cancer
Apoptosis remains a physiological form of cell death, which enables elimination of damaged cells. Apoptosis is also called programmed cell death, because this process is exactly regulated by several genes including P53,...
Depression and Anxiety in Patients with Cancer
Patients who suffer from cancer are particularly exposed to anxiety and depression. The reasons are both biological changes in the body and social factors. In spite of a large prevalence of these disorders only 20% of th...
Skrajna hiponatremia w przebiegu zespołu niedostosowanego wydzielania hormonu antydiuretycznego (SIADH) u chorego na drobnokomórkowego raka płuca – opis przypadku i przegląd piśmiennictwa
Wstęp: Celem pracy jest przedstawienie przypadku pełnoobjawowego zespołu SIADH ze skrajną hiponatremią u chorego na drobnokomórkowego raka płuca w początkowym etapie leczenia cytostatykami. Opis przypadku: 64-letniego m...